Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study

1. Martin, M.
2. Roche, H.
3. Pinter, T.
4. Crown, J.
5. Kennedy, M.J.
6. Provencher, L.
7. Priou, F.
8. Eiermann, W.
9. Adrover, E.
10. Lang, I.
11. Ramos, M.
12. Latreille, J.
13. Jagiełło-Gruszfeld, A.
14. Pienkowski, T.
15. Alba, E.
16. Snyder, R.
17. Almel, S.
18. Rolski, J.
19. Munoz, M.
20. Moroose, R.
21. Hurvitz, S.
22. Baños, A.
23. Adewoye, H.
24. Hei, Y.-J.
25. Lindsay, M.-A.
26. Rupin, M.
27. Cabaribere, D.
28. Lemmerick, Y.
29. Mackey, J.R.
30. Show all authors +